Pharmaceutical

FibroGen sells China unit to AstraZeneca for $160m

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.

Feb 21, 2025 - 06:00
FibroGen sells China unit to AstraZeneca for $160m
AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.
Read the original article

Tags:

Previous Article

Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks

Next Article

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why the Importer of Record (IoR) is vital in the clinical supply chain ­­

Why the Importer of Record (IoR) is vital in the clinic...

Sep 4, 2024

Why do some women experience UTI pain with no clear infection? A mouse study offers clues

Why do some women experience UTI pain with no clear inf...

Mar 2, 2024

Gilead and Cognizant expand deal to expedite digital transformation

Gilead and Cognizant expand deal to expedite digital tr...

Jul 25, 2023